Abstract Number: 0356 • ACR Convergence 2020
Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes and…Abstract Number: 0990 • ACR Convergence 2020
Interferon Lambda Promotes Human Plasma Cell Differentiation in Lupus and Healthy Donors
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by antinuclear autoantibodies produced by plasma cells. Type I interferon (IFN) are cytokines which…Abstract Number: 1368 • ACR Convergence 2020
Proportions of Patients Achieving a Minimal Disease Activity State upon Treatment with Tildrakizumab in a Psoriatic Arthritis Phase 2b Study
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved in the US, EU, and Australia to treat moderate to severe plaque psoriasis.1 A randomized,…Abstract Number: 0361 • ACR Convergence 2020
Response to Treatment with Ixekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis Based on HLA-B27 Status and Disease Duration
Background/Purpose: In this analysis, we evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or without baseline HLA-B27…Abstract Number: 0994 • ACR Convergence 2020
Does Tofacitinib Impact B Cell Functions?
Background/Purpose: Tofacitinib (tofa) inhibits cytokine signaling mediated by JAK1 JAK3 pathways leading therefore to a decrease in Th17 and an increase of Treg cells. The…Abstract Number: 1369 • ACR Convergence 2020
Efficacy of Tildrakizumab in PsA: DAPSA Remission and Low Disease Activity in PASDAS Through Week 52
Background/Purpose: Tildrakizumab (TIL), an anti–interleukin-23p19 monoclonal antibody, is approved in the US, EU, and Australia for treatment of moderate to severe plaque psoriasis. A randomized,…Abstract Number: 0364 • ACR Convergence 2020
Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Back Pain, Morning Stiffness, Fatigue, and Low Disease Activity in Patients with Active Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial
Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) report pain (70–80%), stiffness (20–40%), and fatigue (50–60%) as the most troubling symptoms. Early diagnosis and sustained improvement…Abstract Number: 1151 • ACR Convergence 2020
Implementation and Initial Experience with a Screening Protocol for Inflammatory Hyperferritinemia
Background/Purpose: Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) epitomize a diverse and deadly group of inflammatory hyperferritinemic syndromes. Early biomarkers distinguishing these syndromes, especially…Abstract Number: 1373 • ACR Convergence 2020
IL-23 Skin and Joint Profiling in Psoriatic Arthritis: Novel Perspectives in Understanding Clinical Responses to IL-23 Inhibitors
Background/Purpose: PsA is a chronic heterogeneous inflammatory condition affecting up to 30% of patients with skin and/or nail psoriasis and the IL-23/IL-17 axis is believed…Abstract Number: 0497 • ACR Convergence 2020
Interleukin-23 Acts Directly on Podocytes and Contributes to the Development of Glomerulonephritis
Background/Purpose: Interleukin (IL)-23 is central in the advancement of an inflammatory response and has been shown to be involved in the pathogenesis of autoimmune diseases.…Abstract Number: 1152 • ACR Convergence 2020
IL-18: A Biomarker That Reflects Disease Activity, Could It Be the Next Disease Activity Measure in Systemic Juvenile Idiopathic Arthritis?
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a childhood arthritis with prominent innate immune activity. Disease presentation and flares could largely mimic infections with fever…Abstract Number: 1383 • ACR Convergence 2020
Tocilizumab Shows Potential in Preserving Lung Function in Systemic Sclerosis with Positive anti-topoisomerase-1 (Scl-70): A Single Centre Cohort Study
Background/Purpose: Recent Phase II (faSScinate) and Phase III (focuSSced) clinical trials of tocilizumab versus placebo in early dcSSc highlighted the potential impact of tocilizumab on…Abstract Number: 0505 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial
Background/Purpose: Axial disease may affect up to 25–70% of psoriatic arthritis (PsA) patients, depending on the definition used. Current evidence on efficacy of biologics in…Abstract Number: 1156 • ACR Convergence 2020
Comparison of Immunological Biomarkers and Lung Histology in Patients with Elevated IL18 – Pulmonary Alveolar Proteinosis and Recurrent Macrophage Activation Syndrome (IL-18PAP-MAS) and Other Inflammatory Lung Diseases
Background/Purpose: Recently, pulmonary alveolar proteinosis (PAP) and recurrent macrophage activation syndrome (MAS) have been reported in rare patients (pts) with systemic juvenile idiopathic arthritis (SJIA)…Abstract Number: 1399 • ACR Convergence 2020
Differential Impacts of TNFa Inhibitors on the Expression of Th Cytokines
Background/Purpose: Inhibition of TNFα has emerged as an effective therapeutic approach for many autoimmune/inflammatory diseases.While the efficacy and safety profile of the five FDA-approved TNFis…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- Next Page »